DOCSLIB.ORG

List of Section 13F Securities, First Quarter, 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Section 13F Securities, First Quarter, 2014 List of Section 13F Securities First Quarter FY 2014 Copyright (c) 2014 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2014, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2014. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(1) and Rule 13f-1] thereunder. Features (1) Additions and Deletions: Revisions made to the list of Section 13(f) securities are indicated in a column titled “STATUS.” The word “ADDED” in the status column opposite the name of a security indicates that the security has become a Section 13(f) security. The word “DELETED” in the status column opposite the name of a security indicates that the security ceases to be a 13(f) security since the date of the last list. (2) List of options: An asterisk is placed next to the name of any security having a listed option and each option is individually listed with its own CUSIP number immediately below the name of the security having the option. A manager reporting holdings of options on its Form13F should use the CUSIP number of the underlying securities to which the option relates. CUSIP descriptions and numerical identification date (copyright 1969 through 2014, American Bankers Association) are used with permission. All rights are reserved. Run Date: 3/24/2014 ** List of Section 13F Securities ** Page 1 Run Time: 14:23 Year: 2014 Qtr: 1 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS C15396 AA 9 CANADIAN SOLAR INC DEBT 4.250% 2/1 ADDED D18190 89 8 * DEUTSCHE BANK AG NAMEN AKT D18190 90 8 DEUTSCHE BANK AG CALL D18190 95 8 DEUTSCHE BANK AG PUT G0083B 10 8 * ACTAVIS PLC SHS G0083B 90 8 ACTAVIS PLC CALL G0083B 95 8 ACTAVIS PLC PUT G0129K 10 4 * AIRCASTLE LTD COM G0129K 90 4 AIRCASTLE LTD CALL G0129K 95 4 AIRCASTLE LTD PUT G0176J 10 9 * ALLEGION PUB LTD CO ORD SHS G0176J 90 9 ALLEGION PUB LTD CO CALL G0176J 95 9 ALLEGION PUB LTD CO PUT G01767 10 5 * ALKERMES PLC SHS G01767 90 5 ALKERMES PLC CALL G01767 95 5 ALKERMES PLC PUT G02602 10 3 * AMDOCS LTD SHS G02602 90 3 AMDOCS LTD CALL G02602 95 3 AMDOCS LTD PUT G0335L 10 2 * AMIRA NATURE FOODS LTD SHS G0335L 90 2 AMIRA NATURE FOODS LTD CALL G0335L 95 2 AMIRA NATURE FOODS LTD PUT G037AX 10 1 * AMBARELLA INC SHS G037AX 90 1 AMBARELLA INC CALL G037AX 95 1 AMBARELLA INC PUT G0408V 10 2 * AON PLC SHS CL A G0408V 90 2 AON PLC CALL G0408V 95 2 AON PLC PUT G0440W 10 0 ANDINA ACQUISITION CORP COM DELETED G0440W 12 6 ANDINA ACQUISITION CORP *W EXP 03/16/201 DELETED G0450A 10 5 * ARCH CAP GROUP LTD ORD G0450A 90 5 ARCH CAP GROUP LTD CALL G0450A 95 5 ARCH CAP GROUP LTD PUT G0457F 10 7 * ARCOS DORADOS HOLDINGS INC SHS CLASS -A - Run Date: 3/24/2014 ** List of Section 13F Securities ** Page 2 Run Time: 14:23 Year: 2014 Qtr: 1 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G0457F 90 7 ARCOS DORADOS HOLDINGS INC CALL G0457F 95 7 ARCOS DORADOS HOLDINGS INC PUT G0464B 10 7 * ARGO GROUP INTL HLDGS LTD COM G0464B 90 7 ARGO GROUP INTL HLDGS LTD CALL G0464B 95 7 ARGO GROUP INTL HLDGS LTD PUT G0471F 10 9 * APCO OIL & GAS INTERNATIONAL SHS G0471F 90 9 APCO OIL & GAS INTERNATIONAL CALL G0471F 95 9 APCO OIL & GAS INTERNATIONAL PUT G0535E 10 6 ASIA PACIFIC WIRE & CABLE CO ORD G05384 10 5 * ASPEN INSURANCE HOLDINGS LTD SHS G05384 90 5 ASPEN INSURANCE HOLDINGS LTD CALL G05384 95 5 ASPEN INSURANCE HOLDINGS LTD PUT G0585R 10 6 * ASSURED GUARANTY LTD COM G0585R 90 6 ASSURED GUARANTY LTD CALL G0585R 95 6 ASSURED GUARANTY LTD PUT G06207 11 5 ATLAS FINANCIAL HOLDINGS INC SHS NEW G0692U 10 9 * AXIS CAPITAL HOLDINGS LTD SHS G0692U 90 9 AXIS CAPITAL HOLDINGS LTD CALL G0692U 95 9 AXIS CAPITAL HOLDINGS LTD PUT G07021 10 1 * CHC GROUP LTD SHS ADDED G07021 90 1 CHC GROUP LTD CALL ADDED G07021 95 1 CHC GROUP LTD PUT ADDED G10082 14 0 * ENERGY XXI BERMUDA LTD USD UNRS SHS G10082 90 0 ENERGY XXI BERMUDA LTD CALL G10082 95 0 ENERGY XXI BERMUDA LTD PUT G1151C 10 1 * ACCENTURE PLC IRELAND SHS CLASS A G1151C 90 1 ACCENTURE PLC IRELAND CALL G1151C 95 1 ACCENTURE PLC IRELAND PUT G1190F 10 7 BLUE CAP REINS HLDGS LTD COM G16249 10 7 * BROOKFIELD PPTY PARTNERS L P UNIT LTD PARTN G16249 90 7 BROOKFIELD PPTY PARTNERS L P CALL G16249 95 7 BROOKFIELD PPTY PARTNERS L P PUT G16252 10 1 * BROOKFIELD INFRAST PARTNERS LP INT UNIT G16252 90 1 BROOKFIELD INFRAST PARTNERS CALL Run Date: 3/24/2014 ** List of Section 13F Securities ** Page 3 Run Time: 14:23 Year: 2014 Qtr: 1 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G16252 95 1 BROOKFIELD INFRAST PARTNERS PUT G16258 10 8 * BROOKFIELD RENEWABLE ENRGY P PARTNERSHIP UNIT G16258 90 8 BROOKFIELD RENEWABLE ENRGY P CALL G16258 95 8 BROOKFIELD RENEWABLE ENRGY P PUT G16962 10 5 * BUNGE LIMITED COM G16962 90 5 BUNGE LIMITED CALL G16962 95 5 BUNGE LIMITED PUT G20045 20 2 * CENTRAL EUROPEAN MEDIA ENTRP CL A NEW G20045 90 2 CENTRAL EUROPEAN MEDIA ENTRP CALL G20045 95 2 CENTRAL EUROPEAN MEDIA ENTRP PUT G21082 10 5 * CHINA YUCHAI INTL LTD COM G21082 90 5 CHINA YUCHAI INTL LTD CALL G21082 95 5 CHINA YUCHAI INTL LTD PUT G2110R 11 4 * CHIPMOS TECH BERMUDA LTD SHS G2110R 90 4 CHIPMOS TECH BERMUDA LTD CALL G2110R 95 4 CHIPMOS TECH BERMUDA LTD PUT G2110U 10 9 CHINA NATURAL RESOURCES INC COM G21101 10 3 * CHINA GERUI ADV MAT GR LTD SHS G21101 90 3 CHINA GERUI ADV MAT GR LTD CALL G21101 95 3 CHINA GERUI ADV MAT GR LTD PUT G21107 10 0 CHINA CORD BLOOD CORP SHS G2112E 14 5 CHINA HYDROELECTRIC CORPORAT *W EXP 01/25/201 DELETED G2113X 10 0 CHINA CERAMICS CO LTD SHS G21174 10 0 * CHINA INFORMATION TECHNOLOGY COM G21174 90 0 CHINA INFORMATION TECHNOLOGY CALL G21174 95 0 CHINA INFORMATION TECHNOLOGY PUT G21490 11 8 CIS ACQUISITION LTD *W EXP 12/18/201 G21490 20 9 CIS ACQUISITION LTD SHS SER A G21490 50 6 CIS ACQUISITION LTD UNIT 99/99/9999 G2266G 10 2 COLLABRIUM JAPAN ACQUISITN C SHS G2266G 11 0 COLLABRIUM JAPAN ACQUISITN C *W EXP 99/99/999 G2266G 12 8 COLLABRIUM JAPAN ACQUISITN C UNIT 99/99/9999 G23773 10 7 * CONSOLIDATED WATER CO INC ORD G23773 90 7 CONSOLIDATED WATER CO INC CALL Run Date: 3/24/2014 ** List of Section 13F Securities ** Page 4 Run Time: 14:23 Year: 2014 Qtr: 1 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G23773 95 7 CONSOLIDATED WATER CO INC PUT G2519Y 10 8 * CREDICORP LTD COM G2519Y 90 8 CREDICORP LTD CALL G2519Y 95 8 CREDICORP LTD PUT G25343 10 7 * COSAN LTD SHS A G25343 90 7 COSAN LTD CALL G25343 95 7 COSAN LTD PUT G2554F 11 3 * COVIDIEN PLC SHS G2554F 90 3 COVIDIEN PLC CALL G2554F 95 3 COVIDIEN PLC PUT G25861 AA 6 CTRIP COM INTERNATIONAL LTD DEBT 0.500% 9/1 G25861 AB 4 CTRIP COM INTERNATIONAL LTD DEBT 1.250%10/1 G27010 10 0 DEHAIER MEDICAL SYSTEMS LIMI SHS G27823 10 6 * DELPHI AUTOMOTIVE PLC SHS G27823 90 6 DELPHI AUTOMOTIVE PLC CALL G27823 95 6 DELPHI AUTOMOTIVE PLC PUT G29183 10 3 * EATON CORP PLC SHS G29183 90 3 EATON CORP PLC CALL G29183 95 3 EATON CORP PLC PUT G29438 10 1 E FUTURE INFORMATION TECH IN SHS G30397 10 6 * ENDURANCE SPECIALTY HLDGS LT SHS G30397 90 6 ENDURANCE SPECIALTY HLDGS LT CALL G30397 95 6 ENDURANCE SPECIALTY HLDGS LT PUT G30401 10 6 * ENDO INTL PLC SHS ADDED G30401 90 6 ENDO INTL PLC CALL ADDED G30401 95 6 ENDO INTL PLC PUT ADDED G3075P 10 1 ENSTAR GROUP LIMITED SHS G3156P 10 3 * ASA GOLD AND PRECIOUS MTLS L SHS G3156P 90 3 ASA GOLD AND PRECIOUS MTLS L CALL G3156P 95 3 ASA GOLD AND PRECIOUS MTLS L PUT G3157S 10 6 * ENSCO PLC SHS CLASS A G3157S 90 6 ENSCO PLC CALL G3157S 95 6 ENSCO PLC PUT G3163G 10 4 CHINA METRO-RURAL HLDGS LTD SHS Run Date: 3/24/2014 ** List of Section 13F Securities ** Page 5 Run Time: 14:23 Year: 2014 Qtr: 1 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G3198U 10 2 * ESSENT GROUP LTD COM G3198U 90 2 ESSENT GROUP LTD CALL G3198U 95 2 ESSENT GROUP LTD PUT G32030 12 7 EURO TECH HOLDINGS CO LTD SHS NEW G3223R 10 8 * EVEREST RE GROUP LTD COM G3223R 90 8 EVEREST RE GROUP LTD CALL G3223R 95 8 EVEREST RE GROUP LTD PUT G32335 10 4 EXCEED COMPANY LTD SHS G3323L 10 0 * FABRINET SHS G3323L 90 0 FABRINET CALL G3323L 95 0 FABRINET PUT G35569 10 5 * FLEETMATICS GROUP PLC COM G35569 90 5 FLEETMATICS GROUP PLC CALL G35569 95 5 FLEETMATICS GROUP PLC PUT G36738 10 5 * FRESH DEL MONTE PRODUCE INC ORD G36738 90 5 FRESH DEL MONTE PRODUCE INC CALL G36738 95 5 FRESH DEL MONTE PRODUCE INC PUT G3682E 12 7 * FRONTLINE LTD SHS G3682E 90 7 FRONTLINE LTD CALL G3682E 95 7 FRONTLINE LTD PUT G3704F 10 2 FUWEI FILMS HLDGS
Load more

Recommended publications
  • R Trader Instruments Cfds and Stocks
    DE SHARES Ticker Company Ticker Company Ticker Company 1COV.DE COVESTRO AG FNTN.DE FREENET AG P1Z.DE PATRIZIA IMMOBILIEN AG AAD.DE AMADEUS FIRE AG FPE.DE FUCHS PETROLUB vz PBB.DE DEUTSCHE PFANDBRIEFBANK AG ACX1.DE BET-AT-HOME.COM AG FRA.DE FRAPORT AG FRANKFURT AIRPORTPFV.DE PFEIFFER VACUUM TECHNOLOGY ADJ.DE ADO PROPERTIES FRE.DE FRESENIUS PSM.DE PROSIEBENSAT.1 MEDIA SE ADL.DE ADLER REAL ESTATE AG G1A.DE GEA PUM.DE PUMA SE ADS.DE ADIDAS AG G24.DE SCOUT24 AG QIA.DE QIAGEN N.V. ADV.DE ADVA OPTICAL NETWORKING SE GBF.DE BILFINGER SE RAA.DE RATIONAL AFX.DE CARL ZEISS MEDITEC AG - BR GFT.DE GFT TECHNOLOGIES SE RHK.DE RHOEN-KLINIKUM AG AIXA.DE AIXTRON SE GIL.DE DMG MORI RHM.DE RHEINMETALL AG ALV.DE ALLIANZ SE GLJ.DE GRENKE RIB1.DE RIB SOFTWARE SE AM3D.DE SLM SOLUTIONS GROUP AG GMM.DE GRAMMER AG RKET.DE ROCKET INTERNET SE AOX.DE ALSTRIA OFFICE REIT-AG GWI1.DE GERRY WEBER INTL AG S92.DE SMA SOLAR TECHNOLOGY AG ARL.DE AAREAL BANK AG GXI.DE GERRESHEIMER AG SAX.DE STROEER SE & CO KGAA BAS.DE BASF SE HAB.DE HAMBORNER REIT SAZ.DE STADA ARZNEIMITTEL AG BAYN.DE BAYER AG HBM.DE HORNBACH BAUMARKT AG SFQ.DE SAF HOLLAND S.A. BC8.DE BECHTLE AG HDD.DE HEIDELBERGER DRUCKMASCHINENSGL.DE SGL CARBON SE BDT.DE BERTRANDT AG HEI.DE HEIDELBERGCEMENT AG SHA.DE SCHAEFFLER AG BEI.DE BEIERSDORF AG HEN3.DE HENKEL AG & CO KGAA SIE.DE SIEMENS AG BIO4.DE BIOTEST AG HLAG.DE HAPAG-LLOYD AG SIX2.DE SIXT SE BMW.DE BAYERISCHE MOTOREN WERKE AGHLE.DE HELLA KGAA HUECK & CO SKB.DE KOENIG & BAUER AG BNR.DE BRENNTAG AG HNR1.DE HANNOVER RUECK SE SPR.DE AXEL SPRINGER SE BOSS.DE HUGO BOSS
    [Show full text]
  • Biotechnology Worldwide
    Biotechnology Worldwide There are several countries that are making special efforts to both develop and capitalise on Biotechnology. Chief amongst them is America, though cutting edge work is also going on in the UK, Ireland, Germany, Korea, Singapore, China and Japan. • America is the world leader in biotechnology, it has 1,379 biotechnology companies and employs 174,000 people. It spends £9 billion on research into biotechnology. • The European market for goods and services dependent on biotechnology is currently estimated at £30 billion and is forecast to exceed £100 billion by the year 2005 • The UK leads Europe in biotechnology and employs 19,000 people • The UK has 300 dedicated biotechnology companies and a further 250-300 involved in broader bioscience related activities • The industrial sectors which stand to benefit from biotechnology are pharmaceutical, agriculture, food and drink, chemicals and environmental technologies • Germany is the second strongest country in Europe, with 332 companies but fewer products in development than the UK. UK The UK biotechnology industry is regarded as second only to the huge effort taking place in the States. UK biotechnology companies generate over a billion pounds in revenue; half of this is pumped back into research and development. The industry has particular strengths, for example: • Britain was a key player in the world wide project of sequencing the 30,000 genes of the human genome. The announcement of the first working draft of the human genome marks a significant step forward in our understanding of the way in which we understand and develop treatments for incurable genetic conditions.
    [Show full text]
  • Etf-Sparpläne
    ETF-SPARPLÄNE ISIN NAME IE00B8KGV557 ISHARES EDGE MSCI EM MIN VOL USD (ACC) IE00B86MWN23 ISHARES EDGE MSCI EUROPE MIN VOLATILITY EUR (ACC) IE00B8FHGS14 ISHARES EDGE MSCI WORLD MIN VOLATILITY USD (ACC) IE00B6SPMN59 ISHARES EDGE S&P 500 MIN VOL USD (ACC) IE00B87G8S03 ISHARES GLOBAL AAA-AA GOV BOND USD (DIST) DE0005933931 ISHARES CORE DAX EUR (ACC) IE0032523478 ISHARES CORP BOND LARGE CAP EUR (DIST) IE00B14X4T88 ISHARES ASIA PACIFIC DIVIDEND USD (DIST) IE00B1W57M07 ISHARES BRIC 50 USD (DIST) DE000A0F5UG3 ISHARES DOW JONES EU SUSTAINABLE EUR (DIST) IE00B6R52143 ISHARES AGRIBUSINESS USD (ACC) IE00B0M62Y33 ISHARES AEX EUR (DIST) DE000A0D8Q23 ISHARES ATX EUR (DIST) IE00B1FZSC47 ISHARES USD TIPS USD (ACC) IE00B14X4S71 ISHARES USD TREASURY BOND 1-3Y USD (DIST) IE00B1FZS798 ISHARES USD TREASURY BOND 7-10Y USD (DIST) IE00B1FZSD53 ISHARES GBP INDEX-LINKED GILTS GBP (DIST) IE00B6QGFW01 ISHARES EMERGING ASIA LOCAL GOV BOND USD (DIST) IE00B5M4WH52 ISHARES JPM EM LOCAL GOV BOND USD (DIST) IE00B3DKXQ41 ISHARES EURO AGGREGATE BOND EUR (DIST) IE00B3F81R35 ISHARES CORE EURO CORP BOND EUR (DIST) IE00B4L60045 ISHARES EURO CORP BOND 1-5Y EUR (DIST) IE00B4L5ZG21 ISHARES EURO CORP BOND EX-FIN EUR (DIST) IE00B4L5ZY03 ISHARES EURO CORP BOND EX-FIN 1-5Y EUR (DIST) IE00B6X2VY59 ISHARES EURO CORP BOND INT. RATE HEDGED (DIST) IE00B14X4Q57 ISHARES EURO GOV BOND 1-3Y EUR (DIST) IE00B4WXJH41 ISHARES EURO GOV BOND 10-15Y EUR (DIST) IE00B1FZS913 ISHARES EURO GOV BOND 15-30Y EUR (DIST) IE00B1FZS681 ISHARES EURO GOV BOND 3-5Y EUR (DIST) IE00B4WXJG34 ISHARES EURO GOV BOND
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • Mount Allison University Endowment Fund Holdings As of December 31, 2017
    Mount Allison University Endowment Fund Holdings As of December 31, 2017 Security Name Market Value ($Can) EQUITY HOLDINGS Canadian Holdings 5N PLUS INC $ 155 ABSOLUTE SOFTWARE CORP $ 851 ACADIAN TIMBER CORP $ 302 ADVANTAGE OIL & GAS LTD $ 283,788 AECON GROUP INC $ 1,728 AFRICA OIL CORP $ 684 AG GROWTH INTERNATIONAL INC $ 1,163 AGELLAN COMMERCIAL REAL ESTATE $ 349 AGF MANAGEMENT LTD $ 990 AGNICO-EAGLE MINES LTD $ 427,207 AGT FOOD AND INGREDIENTS INC $ 653 AIMIA INC $ 832 AIR CANADA INC $ 325,411 AIRBOSS OF AMERICA CORP $ 315 ALACER GOLD CORP $ 1,289 ALAMOS GOLD INC $ 2,216 ALAMOS GOLD INC NEW COM CLASS A $ 4,877 ALARIS ROYALTY CORP $ 1,107 ALGOMA CENTRAL CORP $ 330 ALIMENTATION COUCHE-TARD INC $ 98,854 ALIO GOLD INC $ 472 ALLIED PROPERTIES REAL ESTATE INVESTMENT TRUST $ 2,575 ALTIUS MINERALS CORP $ 1,233 ALTUS GROUP LTD/CANADA $ 1,916 ANDREW PELLER LTD $ 1,448 ARGONAUT GOLD INC $ 656 ARTIS REAL ESTATE INVESTMENT TRUST $ 1,539 ASANKO GOLD INC $ 209 ATCO LTD $ 119,947 ATHABASCA OIL COP $ 703 ATS AUTOMATION TOOLING SYSTEMS INC $ 1,769 AURICO METALS INC $ 311 AUTOCANADA INC $ 1,128 AVIGILON CORP $ 1,258 B2GOLD CORP $ 29,898 BADGER DAYLIGHTING LTD $ 1,525 BANK OF MONTREAL $ 725,449 BANK OF NOVA SCOTIA $ 2,019,757 BARRICK GOLD CORP $ 459,749 BAYTEX ENERGY CORP $ 1,213 BCE INC $ 791,441 BELLATRIX EXPLORATION LTD $ 94 BIRCHCLIFF ENERGY LTD $ 1,479 BIRD CONSTRUCTION INC $ 731 1 Mount Allison University Endowment Fund Holdings As of December 31, 2017 Security Name Market Value ($Can) BLACK DIAMOND GROUP LTD $ 95 BLACKBERRY LIMITED $ 151,777 BLACKPEARL RESOURCES INC $ 672 BOARDWALK REAL ESTATE INVESTMENT TRUST $ 1,610 BONAVISTA ENERGY CORP $ 686 BONTERRA ENERGY CORP $ 806 BORALEX INC $ 2,276 BROOKFIELD ASSET MANAGEMENT INCORPORATED $ 672,870 BROOKFIELD INFRASTRUCTURE PARTNERS L.P.
    [Show full text]
  • Biopartnering Executive Summary
    BIOWORLD® BIOPARTNERING REPORT 2009: STRATEGIES AND PARADIGMS OF THE DEAL EXECUTIVE SUMMARY By Michael Harris, BioWorld Executive Editor and Amanda Lyle, BioWorld Managing Editor LIST OF CONTENTS Introduction and Analysis Trends Depressing First Half of 2008 in Worldwide Public Markets Drug/Device Combos Could Salvage Dropped Compounds A Match Made in Heaven; R&D Productivity Via Partnering Drug and Medical Device Deals: A Different Type of Partnership As Big Pharma Model Falters, Biotech Rides to the Rescue Deals to M&As: The Culture of False-Flagging, Shape-Shifting Notable Deals Autoimmune and Inflammation Deals Immunomedics Inks Potential $620M Deal with Nycomed ARYx Seeking New Partner for GI Program after P&G Bails Out UCB Licenses Keppra, Cimzia Rights in Japan Alizyme, Norgine Team Up in $67M Marketing Deal Bionomics Signs Merck Serono in MS, Autoimmune Partnership TransPharma Gets $35M in Osteo Deal with Lilly QLT Sells Acne Gel Product Aczone for $150M to Allergan Start-up TFT Adds NF-Kappa B Decoy Program from Anesiva Early Stage Antibody Nets EUSA $44M from GSK Scil, Pfizer Enter $250M Deal for Preclinical Osteo Drug Catalyst Partners with Centocor for Engineered Protease Drugs Galapagos Inks $395M Deal with Lilly for Osteo Drugs Alba Inks Ex-U.S./Japan Deal with Shire for Celiac Drug Excaliard Snags $15.5M and Isis Fibrosis Drugs Galapagos and Janssen in RA Partnership Axcan, Cellerix Deal for Adult Stem Cell Therapy Radius Grants Novartis Option to BA058 in Potential $500M Deal Microbia, Forest Collaborate: Up to $330M for
    [Show full text]
  • Merrick School of Business 2012 Global Field Study Opportunities Israel (March 16-24 2011)
    Merrick School Of Business 2012 Global Field Study Opportunities Israel (March 16-24 2011) Spring Break 2012 Dean Darlene Smith Dr. Michael Laric Overview Pre-Trip Preparation -- Three sessions – In early January, February, March – The Start-Up Nation as basis – Lectures about the country and background – Trip orientation and preparation Trip -- Spring Break, March 16 – 24 Post Trip -- One session – In April – Summary and debriefing Trip Themes Business (Start-up Nation) • Entrepreneurship • Innovation • Growing economy Socio-cultural & history • Unique culture and environment • Most non USA companies on NASDAQ • Origins of major religions • Unique history dating back to biblical times Tentative Trip Itinerary Friday March 16 -- Baltimore to Israel (depart from BWI) Saturday March 17 -- Arrival & transfer to Jerusalem. Sunday March 18 – Tour of old and new city (Christian Quarter, Stations of the Cross, Armenian Quarter, etc) Monday, March 19 – Friday, March 23 – Site Visits in Jerusalem, Ashkelon, Tel Aviv Saturday – Depart Tel Aviv; arrive at BWI Start-up Nation: The Story of Israel's Economic Miracle Dan Senor and Saul Singer Start-up Nation • Examines how – A nation of immigrants – 60-year old – And a population of 7.1 million • Reached a high rate of economic growth • Called Silicon “Wadi” • "at the start of 2009, some 63 Israeli companies were listed on the NASDAQ, more than those of any other foreign country.“1 1 JAMES K. GLASSMAN (2009). "Where Tech Keeps Booming In Israel, a clustering of talent, research universities and venture capital..". Wall Street Journal. (November 23) Start-up Nation Selected Reviews • In 2010, this book was reviewed (David Brooks) and ranked fifth on the business best-seller list of the The New York Times.
    [Show full text]
  • Saving UK Biotech
    January 22, 2009 Saving UK Biotech Evaluate Vantage While news of the death of the UK biotechnology industry maybe exaggerated, despite a recent spate of companies falling into administration and big pharma picking off some of the best and brightest hopes in the sector, a report into the state of the industry by the Bioscience Innovation and Growth Team published today indicated that an ambulance might be called for unless drastic measures are taken. Chief among the calls from the group, which is supported by the UK’s industry champion, the Biotech Industry Association, was the need for more tax incentives, especially for the pharmaceutical industry to make investments in smaller biotechnology businesses more attractive, in order to ensure the health of the sector. Speedier approvals The National Institute for Health and Clinical Excellence (NICE), which decides on which drugs will be used in the UK’s health service was also identified as a potential barrier to drug innovation, due to the length of time it takes to decide on whether to use drugs. Sir David Cooksey, who was presenting the review on progress made in the industry since 2003, said that the average time between approval of a drug and its introduction by NICE often equated to a third of the patent life of the drug, leaving innovator companies less time to recoup the cost of drug discovery and potentially driving prices up. But the most controversial proposal today was the suggestion that drugs in phase II be used commercially in the UK, whilst waiting for approval, allowing orginators to recoup the cost of development at an earlier stage.
    [Show full text]
  • ESSAYS on the DRUG DISCOVERY INNOVATION SYSTEM By
    ESSAYS ON THE DRUG DISCOVERY INNOVATION SYSTEM by Alfred Sarkissian A Dissertation Submitted to the Graduate Faculty of George Mason University in Partial Fulfillment of The Requirements for the Degree of Doctor of Philosophy Public Policy Committee: _______________________________________ David M. Hart, Chair _______________________________________ Siona Listokin _______________________________________ Naoru Koizumi Ruben Jacobo-Rubio, External Reader _______________________________________ Sita N. Slavov, Program Director _______________________________________ Mark J. Rozell, Dean Date: __________________________________ Fall Semester 2017 George Mason University Fairfax, VA Essays on the Drug Discovery Innovation System A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at George Mason University by Alfred Sarkissian Master of Arts Allameh Tabatabai University, 2002 Bachelor of Arts Azad University, 1997 Director: David M. Hart, Professor Department of Public Policy; Schar School of Policy and Government Fall Semester 2017 George Mason University Fairfax, VA Copyright 2017 Alfred Sarkissian All Rights Reserved ii ACKNOWLEDGEMENTS I need to express my deepest gratitude to my committee chair Prof. David M. Hart for his advice, mentorship, and patience in the course of this dissertation and the program. I also owe a sincere appreciation to other committee members Prof. Naoru Koizumi and Prof. Siona Listokin. Prof. Mark Addleson was forthcoming with his time during the field stage
    [Show full text]
  • Biotech Anglais270
    L’INFORMATION STRATÉGIQUE DE L’ESPACE EUROPÉEN DE L’INNOVATION Biotechnologies FINANCES IAL EC & P S TH HALF 2005S N° 270 • December 26th 2005 11 HOUR nd 2 L www.biotech-finances.com A € D E 2005: The European Giant Sommaire Stirs from Slumber 11th hour • 2005: The European Giant Stirs 2004 was a disappointment for the biotech and medtech commu- from Slumber ............................p. 1-3 nity. IPOs failed, new finance proved difficult and complicated to Special €Deals find, and attempts at consolidation were stillborn. This meant that many players and observers in the life sciences industry went into The British Isles 2005 believing that mergers and acquisitions were likely to be the • « Biotech in UK are ready to explore new business models » ..............p. 4 main salvation of biotech and medtech. • « There is a lot of interest on the Irish part in going down the IPO road on AIM » ............................p. 4 And yet, 2005 has produced a remarkably good vintage! An IPO window France opened and a number of impressive financing rounds have been achie- • « Technology Transfer has become one major stake » ......................p. 7 ved. The recovery also saw successful consolidation take place. Opportu- nism and opportunity have been the watchwords of the year. German speaking countries The wounds sustained by the biotech industry after the stock market • « Many companies have products in Phase II or Phase III » ............p. 8 bubble burst seem to be healing. Youthful exuberance has returned. More • « We remain positive about the mature projects are now being presented to investors - who themelves prospects for 2006 »......................p.
    [Show full text]
  • Public Affairs and Lobbying Register
    Public Affairs and Lobbying Register 3x1 Offices: 16a Walker Street, Edinburgh EH3 7LP 210 Borough High Street, London SE1 1JX 26-28 Exchange Street, Aberdeen, AB11 6PH OFFICE(S) Address: 3x1 Group, 11 Fitzroy Place, Glasgow, G3 7RW Tel: Fax: Web: CONTACT FOR PUBLIC AFFAIRS [email protected] LIST OF EMPLOYEES THAT HAVE CONDUCTED PUBLIC AFFAIRS SERVICES Ailsa Pender Cameron Grant Katrine Pearson Lindsay McGarvie Patrick Hogan LIST OF CLIENTS FOR WHOM PUBLIC AFFAIRS SERVICES HAVE BEEN PROVIDED Atos North British Distillery Scottish Child Abuse Inquiry SICPA The Scottish Salmon Company Viridor Public Affairs and Lobbying Register Aiken PR OFFICE(S) Address: 418 Lisburn Road, Belfast, BT9 6GN Tel: 028 9066 3000 Fax: 028 9068 3030 Web: www.aikenpr.com CONTACT FOR PUBLIC AFFAIRS [email protected] LIST OF EMPLOYEES THAT HAVE CONDUCTED PUBLIC AFFAIRS SERVICES Claire Aiken Donal O'Neill John McManus Lyn Sheridan Shane Finnegan LIST OF CLIENTS FOR WHOM PUBLIC AFFAIRS SERVICES HAVE BEEN PROVIDED Diageo McDonald’s Public Affairs and Lobbying Register Airport Operators Associaon OFFICE(S) Address: Airport Operators Association, 3 Birdcage Walk, London, SW1H 9JJ Tel: 020 7799 3171 Fax: 020 7340 0999 Web: www.aoa.org.uk CONTACT FOR PUBLIC AFFAIRS [email protected] LIST OF EMPLOYEES THAT HAVE CONDUCTED PUBLIC AFFAIRS SERVICES Ed Anderson Henk van Klaveren Jeff Bevan Karen Dee Michael Burrell - external public affairs Peter O'Broin advisor Roger Koukkoullis LIST OF CLIENTS FOR WHOM PUBLIC AFFAIRS SERVICES HAVE BEEN PROVIDED N/A Public Affairs and
    [Show full text]
  • Geographic Listing by Country of Incorporation
    FOREIGN COMPANIES REGISTERED AND REPORTING WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION December 31, 2010 Geographic Listing by Country of Incorporation COMPANY COUNTRY MARKET Antigua Sinovac Biotech Ltd. Antigua Global Mkt Argentina Alto Palermo S.A. Argentina Global Mkt Banco Macro S.A. Argentina NYSE BBVA Banco Frances S.A. Argentina NYSE Cresud Sacif Argentina Global Mkt Empresa Distribuidora y Comercializadora Norte S.A. - Edenor Argentina NYSE Grupo Financiero Galicia S.A. Argentina Global Mkt IRSA Inversiones y Representacions, S.A. Argentina NYSE MetroGas S.A. Argentina OTC Nortel Inversora S.A. Argentina NYSE Pampa Energia SA Argentina NYSE Petrobras Argentina S.A. Argentina NYSE Telecom Argentina S.A. Argentina NYSE Transportadora de Gas del Sur S.A. Argentina NYSE YPF S.A. Argentina NYSE Australia Allied Gold Ltd. Australia OTC Alumina Ltd. Australia NYSE BHP Billiton Ltd. Australia NYSE Genetic Technologies Ltd. Australia Global Mkt Metal Storm Ltd. Australia OTC Novogen Ltd. Australia Global Mkt Orbital Corp Ltd. Australia OTC Prana Biotechnology Ltd. Australia Cap. Mkt Progen Pharmaceuticals Ltd. Australia OTC Rio Tinto Ltd. Australia OTC Samson Oil & Gas Ltd. Australia NYSE-Amex Sims Metal Management Ltd. Australia NYSE Westpac Banking Corp. Australia NYSE Bahamas Calpetro Tankers (Bahamas I) Ltd. Bahamas OTC - Debt Calpetro Tankers (Bahamas II) Ltd. Bahamas OTC - Debt Calpetro Tankers (Bahamas III) Ltd. Bahamas OTC - Debt Ultrapetrol (Bahamas) Ltd. Bahamas Global Mkt Belgium Anheuser-Busch Inbev SA/NV Belgium NYSE Etablissements Delhaize Freres & Cie - Le Lion Belgium NYSE Page 1 COMPANY COUNTRY MARKET Bermuda AllShips Ltd. Bermuda OTC Alpha and Omega Semiconductor Ltd. Bermuda Global Mkt Asia Pacific Wire & Cable Corp.
    [Show full text]